ES2164883T3 - Compuestos y metodos para la diagnosis de la leishmaniasis. - Google Patents

Compuestos y metodos para la diagnosis de la leishmaniasis.

Info

Publication number
ES2164883T3
ES2164883T3 ES96912940T ES96912940T ES2164883T3 ES 2164883 T3 ES2164883 T3 ES 2164883T3 ES 96912940 T ES96912940 T ES 96912940T ES 96912940 T ES96912940 T ES 96912940T ES 2164883 T3 ES2164883 T3 ES 2164883T3
Authority
ES
Spain
Prior art keywords
compounds
leishmaniasis
leishmania
useful
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96912940T
Other languages
English (en)
Inventor
Steven G Reed
Yasir A W Skeiky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Corixa Corp
Original Assignee
Corixa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corixa Corp filed Critical Corixa Corp
Application granted granted Critical
Publication of ES2164883T3 publication Critical patent/ES2164883T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905Protozoa
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/975Kit
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82Proteins from microorganisms
    • Y10S530/822Protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Semiconductor Integrated Circuits (AREA)
  • Testing, Inspecting, Measuring Of Stereoscopic Televisions And Televisions (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBEN COMPUESTOS Y PROCEDIMIENTOS PARA DIAGNOSTICAR LA INFECCION POR LEISHMANIA. LOS COMPUESTOS DESCRITOS INCLUYEN POLIPEPTIDOS QUE CONTIENEN AL MENOS UN EPITOPO DEL ANTIGENO RIBOSOMICO ACIDO DE LEISHMANIA CHAGASI LCPO, O UN VARIANTE DEL MISMO. ESTOS COMPUESTOS RESULTAN UTILES EN UNA DIVERSIDAD DE INMUNOENSAYOS PARA DETECTAR LA INFECCION POR LEISHMANIA Y PARA IDENTIFICAR INDIVIDUOS CON INFECCIONES ASINTOMATICAS QUE PROBABLEMENTE PUEDEN PROGRESAR HACIA UNA LEISHMANIASIS VISCERAL AGUDA. LOS COMPUESTOS POLIPEPTIDICOS ADEMAS RESULTAN UTILES EN VACUNAS Y COMPOSICIONES FARMACEUTICAS PARA EVITAR LA LEISHMANIASIS.
ES96912940T 1995-04-21 1996-04-19 Compuestos y metodos para la diagnosis de la leishmaniasis. Expired - Lifetime ES2164883T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/428,414 US5912166A (en) 1995-04-21 1995-04-21 Compounds and methods for diagnosis of leishmaniasis

Publications (1)

Publication Number Publication Date
ES2164883T3 true ES2164883T3 (es) 2002-03-01

Family

ID=23698799

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96912940T Expired - Lifetime ES2164883T3 (es) 1995-04-21 1996-04-19 Compuestos y metodos para la diagnosis de la leishmaniasis.

Country Status (9)

Country Link
US (1) US5912166A (es)
EP (2) EP1179733A1 (es)
AT (1) ATE208500T1 (es)
AU (1) AU5559496A (es)
BR (1) BR9608016A (es)
DE (1) DE69616777D1 (es)
ES (1) ES2164883T3 (es)
PT (1) PT824699E (es)
WO (1) WO1996033414A2 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607731B1 (en) 1995-09-22 2003-08-19 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6613337B1 (en) 1997-02-12 2003-09-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6500437B1 (en) 1995-09-22 2002-12-31 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6375955B1 (en) * 1995-09-22 2002-04-23 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
US6365165B1 (en) 1995-09-22 2002-04-02 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of Leishmaniasis
US6638517B2 (en) 1995-09-22 2003-10-28 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
WO1998035045A2 (en) * 1997-02-12 1998-08-13 Corixa Corporation Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ES2133236B1 (es) * 1997-06-27 2000-04-16 Leti Lab Gen quimerico formado por las secuencias de dna que codifican los determinantes antigenicos de cuatro proteinas de l. infantum, aplicable para el diagnostico serologico de leishmaniosis canina y proteina obtenida.
EP1624063B1 (en) * 1998-12-23 2009-04-22 Laboratorios LETI, S.L. Chimeric gene encoding the antigenic determinants of four proteins of L. infantum
ES2273519T3 (es) * 1998-12-23 2007-05-01 C.B.F. Leti S.A. Gen quimerico que codifica los determinantes antigenicos de cuatro proteinas de l. infantum.
US6972198B2 (en) 1999-02-26 2005-12-06 Cyclacel, Ltd. Methods and compositions using protein binding partners
CN1300772A (zh) * 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽-人酸性核糖体磷蛋白16和编码这种多肽的多核苷酸
US20040241168A1 (en) * 2001-03-16 2004-12-02 O'daly Jose A. Compositions and methods for the treatment and clinical remission of psoriasis
US6673351B1 (en) 2001-03-16 2004-01-06 Astralis, Llc Compositions and methods for the treatment and clinical remission of psoriasis
ATE457316T1 (de) 2003-12-26 2010-02-15 All India Inst Med Polypeptide zur diagnose und therapie von leishmaniasen
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
WO2007081779A2 (en) * 2006-01-05 2007-07-19 Genentech, Inc. Methods of determining cutoff points
BRPI0710155A2 (pt) 2006-04-10 2011-08-23 Infectious Disease Res Inst Inc compostos e métodos para diagnóstico e tratamento de leishmaniose
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
US7831108B2 (en) 2006-12-13 2010-11-09 Adobe Systems Incorporated Universal front end for masks, selections, and paths
EP2291394B1 (en) 2008-07-03 2017-03-15 Infectious Disease Research Institute Fusion proteins and their use in the diagnosis and treatment of leishmaniasis
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
RU2558233C2 (ru) * 2009-07-13 2015-07-27 Лабораториос Лети, С.Л. Диагностика паразитарного заболевания, такого как лейшманиоз, с использованием экстракта рибосомальных белков (rpe)
US8406566B1 (en) 2010-05-27 2013-03-26 Adobe Systems Incorporated Methods and apparatus for soft edge masking
BRPI1003744B1 (pt) * 2010-06-08 2021-10-26 Universidade Federal De Ouro Preto E-ntpdases recombinantes, uso na produção de kit de diagnóstico para detecção de anticorpos nas leishmanioses causadas por espécies do gênero leishmania
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
WO2014160987A2 (en) 2013-03-28 2014-10-02 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
KR102748354B1 (ko) 2016-06-01 2024-12-31 액세스 투 어드밴스드 헬스 인스티튜트 사이징제를 함유하는 나노명반 입자
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0197062B1 (fr) * 1984-10-01 1991-01-09 Institut Pasteur Anticorps monoclonaux anti-leishmania, hybridomes secreteurs de ces anticorps, antigenes de leishmania reconnus par ces anticorps, procede d'obtention et applications de ces anticorps monoclonaux et de ces antigenes
IL82740A0 (en) * 1987-06-01 1987-12-20 Yeda Res & Dev Assay for leishmaniasis
FR2619220B1 (fr) * 1987-08-03 1993-03-26 Pasteur Institut Antigenes specifiques de leishmania et leur procede de preparation, profils antigeniques contenant ces antigenes et leur application au diagnostic des leishmanioses viscerales.
US5304371A (en) * 1992-02-14 1994-04-19 Lasys Corporation Peptide for diagnosing and immunizing against T. cruzi infection
US5411865A (en) * 1993-01-15 1995-05-02 Iasys Corporation Method of detecting anti-leishmania parasite antibodies

Also Published As

Publication number Publication date
EP1179733A1 (en) 2002-02-13
EP0824699B1 (en) 2001-11-07
US5912166A (en) 1999-06-15
MX9708121A (es) 1998-06-30
PT824699E (pt) 2002-04-29
WO1996033414A2 (en) 1996-10-24
DE69616777D1 (de) 2001-12-13
EP0824699A2 (en) 1998-02-25
BR9608016A (pt) 1999-03-02
ATE208500T1 (de) 2001-11-15
WO1996033414A3 (en) 1996-11-21
AU5559496A (en) 1996-11-07

Similar Documents

Publication Publication Date Title
BR9608016A (pt) Compostos e processos para diagnóstico de leishmaniasis
ES2180754T3 (es) Compuestos y metodos para la deteccion de infeccion por t. cruzi.
ES2032802T3 (es) Sucedaneo de la sangre, semisintetico, extrapuro.
AR019818A1 (es) Un inmunoconjugado de miostatina.
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
IT8920207A0 (it) Procedimento per la preparazione di perfluoropolieteri perossidici.
ATE116993T1 (de) Saponin-hilfsmittel.
BR0016066A (pt) Compostos e métodos para tratamento e diagnóstico de infecção clamidial
ES2166779T3 (es) Complejos inmunogenicos del hiv.
ATE284710T1 (de) Adjuvans für vitale impfstoffe
PT98156A (pt) Um processo de preparacao de uma composicao de vacina
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
PT854924E (pt) Antigenios de leishmania para uso na terapia e diagnostico da leishmaniose
IT1163001B (it) Procedimento per la preparazione di 4' epidaunorubicina 3', 4' diepidaunorubicina e corrispondenti analoghi della doxorubicina
IT8248474A0 (it) Antigene anti-malarico, procedimento per la sua preparazione e vaccino che lo contiene
ES2094112T3 (es) Oligopeptidos y su uso para el diagnostico y vacunacion relacionados con el sida y el crs.
IT8920269A0 (it) Procedimento per la preparazione di metacrilati di alcooli fluorurati.
ES2043614T3 (es) Procedimiento para la preparacion de un compuesto bactericida.
ES2053712T3 (es) Un antigeno proteico reactivo y fragmentos del mismo.
ES2118720T3 (es) Produccion y utilizacion de agentes antihelminticos e inmunogenos protectores.
ES2059305T5 (es) Proteina del virus de la seudorrabia.
ES2037682T3 (es) Procedimiento para la preparacion de composiciones farmaceuticas empleando quitosanos metilados.
DK138886A (da) Anaplasma marginale-antigen eller fragmenter heraf til anvendelse ved vaccination eller diagnose samt vaccine, der indeholder dette
ES2308850T3 (es) Anticuerpos para antigenos de celulas de langerhans de mamiferos y sus usos.
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 824699

Country of ref document: ES